Clinical trial completion rates decline during COVID-19 pandemic

Clinical trial completion rates decline during COVID-19 pandemic
Social distancing and lockdowns may have reduced the spread of COVID-19, but researchers from Penn State College of Medicine also report those actions may have affected clinical researchers ability to finish trials. Study completion rates dropped worldwide between 13% and 23%, depending on the type of research sponsor and geographic location, between April and October 2020.


Researchers previously reported that more than 80% of clinical trials suspended between March 1 and April 26, 2020, noted the pandemic as their chief reason for halting activity. Patient enrollment in studies was lower in April 2020, compared to April 2019. Arthur Berg, associate professor of public health sciences, and Nour Hawila, a biostatistics doctoral candidate, investigated how these trends may have affected the completion of clinical trials.

The researchers examined more than 117,000 trials in the United States, Europe, Asia and other regions to study whether the pandemic affected clinical research. Their goal was to assess how the pandemic s mitigation efforts and financial setbacks may have contributed to decreased clinical trial enrollment and completion.

"The pandemic has made it more difficult for researchers to recruit and follow up on patients in clinical trials," said Hawila, a research assistant from the Department of Public Health Sciences. "This analysis revealed that the impact was substantial -- particularly for trials funded by government, academic or medical entities."

Hawila and Berg analyzed data from, a website that contains information on the status of thousands of clinical trials in the U.S. Pre-COVID-19 enrollment and completion data was pulled from March 2017 to February 2020. The post-COVID-19 period was defined as April through October 2020.

However, some regions fared better than others during the pandemic. Egypt experienced an increase in both submitted (69%) and completed (73%) clinical trials. Berg explained that the rise is likely in response to the country s recent parliamentary bill governing medical research.

"Clinical research response to the pandemic has been robust," said Berg, a Penn State Cancer Institute researcher and biostatistics doctoral program director. "But the impact of the pandemic on other types of clinical trials will be felt for decades to come. However, as demonstrated in Egypt, timely governmental action may be able to make a difference in reversing the pandemic s impact on research."

Materials provided by Penn State . Original written by Zachary Sweger. Note: Content may be edited for style and length.

Penn State. "Clinical trial completion rates decline during COVID-19 pandemic." ScienceDaily. ScienceDaily, 7 April 2021. .

Penn State. "Clinical trial completion rates decline during COVID-19 pandemic." ScienceDaily. (accessed April 7, 2021).



Dec. 3, 2020 — New research has found that Chicago neighborhoods with barriers to social distancing, including limited access to broadband internet and low rates of health insurance, had more COVID-19 deaths in ...

Nov. 5, 2020 — Research shows that Japan s noncompulsory state of emergency generally succeeded in reducing human movement. A recent study used mobile phone location data for January-April 2020 to record and ...

Oct. 14, 2020 — Scientists have found that particulate matter concentrations in China dropped by an unprecedented 29.7 percent, and by 17.1 percent in parts of Europe, during lockdowns that took place between Feb. 1 ...

Apr. 30, 2016 — Although the publication of results of clinical trials carried out in the USA within 12 months of their completion has been mandatory since 2007, an astoundingly high number of Phase III radiotherapy ...
News Topics :
For the hundreds of thousands of people enrolling in clinical trials every yearand for whom experimental therapies can offer a last hopea new report provides some welcome news Enrollment in...
The COVID 19 pandemic has impacted virtually every aspect of cancer care and research from introducing new risks for cancer patients to disrupting the delivery of cancer treatment and the continuity...
Schools are closing again in response to surging levels of COVID 19 infection, but staging randomised trials when students eventually return could help to clarify uncertainties around when we should send...
A new study using human genetics suggests researchers should prioritize clinical trials of drugs that target two proteins to manage COVID 19 in its early stages. advertisement The findings appeared online...
The first published data from the Anti Amyloid Treatment in Asymptomatic Alzheimer s Disease A4 study supports the hypothesis that higher levels of the amyloid protein in the brain represent an...